{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:34:55Z","timestamp":1784543695714,"version":"3.55.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the imaging appearances and treatment response patterns of the pancreatic neuroendocrine tumors (panNETs) following radiofrequency ablation (RFA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      From an internal database, 17 patients (8 male; mean age: 67\u00b114\u00a0y) with 18 pathology-proven, localized, nonfunctioning panNETs &lt;3\u00a0cm who underwent EUS-RFA for curative intent were included. A total of 32 preablation and 33 postablation scans were included (CT, MRI, or\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET). Lesion size and enhancement on CT\/MRI were independently assessed by 2 readers, while SUVmax was extracted from the original PET reports by a separate reviewer. The Wilcoxon signed-rank and McNemar tests were performed. Treatment response is defined as a complete response (loss of enhancement and SUVmax), a partial response (decrease in size, enhancement, or SUVmax), or no response (no change).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean lesion size decreased from 1.4\u200b\u200b\u200b\u200b\u200b\u200b\u00b10.5\u200b\u00a0cm preablation to 0.3\u00b10.5\u00a0cm postablation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001). Mean SUVmax declined from 17.3\u00b111.2 to 3.1\u00b16.0 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Hyperenhancement was present in 15\/18 (83.3%) lesions preablation versus 5\/18 (27.8%) postablation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01). Of these 15 hyperenhancing lesions, 11 were solid, 3 were cystic, and 1 was mixed cystic and solid. Complete response occurred in 12\/18 (66.7%) lesions, with either complete disappearance 5\/12 (41.4%) or bland cavity formation 7\/12 (58.5%). Partial response occurred in 5\/18 (27.8%) lesions; 4\/5 decreased in size (mean\u00b1SD: 1.4\u00b10.5\u00a0cm preablation vs. 0.6\u00b10.7\u00a0cm postablation), and 3\/5 demonstrated decreased SUVmax. One patient with partial response underwent 2 repeat ablations with an ultimate decrease in SUVmax from 34.1 to 5.9. One solid, hyperenhancing pancreatic body lesion demonstrated no response (1.3\u00a0cm); preablation SUVmax was 10.8, but they did not undergo postablation DOTATATE PET. One patient developed postablation pancreatitis. Mean clinical follow-up was 650 days (423).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RFA is an emerging treatment for small, nonfunctioning panNET. Postablation imaging findings most commonly included complete resolution of the tumor, decreased enhancement, decreased SUVmax, and formation of a bland cavity. As interest in this technique continues to grow, radiologists\u2019 familiarity with expected post-treatment imaging appearances and their associated response patterns is essential for accurate assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rct.0000000000001850","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:00:09Z","timestamp":1770620409000},"page":"509-519","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Imaging Features of Pancreatic Neuroendocrine Tumors Following Radiofrequency Ablation: Early Experience"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-8370","authenticated-orcid":false,"given":"Samantha","family":"Platt","sequence":"first","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Gonda","sequence":"additional","affiliation":[{"name":"Gastroenterology, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Asare","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Melamud","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prahan","family":"Chetlur","sequence":"additional","affiliation":[{"name":"Gastroenterology, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchan","family":"Huang","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260713","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","article-title":"Endocrine tumours of the pancreas","volume":"5","author":"\u00d6berg","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R2-20260713","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.3390\/ijerph18178895","article-title":"Imaging of pancreatic neuroendocrine neoplasms","volume":"18","author":"Chiti","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R3-20260713","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1148\/rg.2020200025","article-title":"Pancreatic neuroendocrine neoplasms: 2020 update on pathologic and imaging findings and classification","volume":"5","author":"Khanna","year":"2020","journal-title":"Radiographics"},{"key":"R4-20260713","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAP.0000000000000201","article-title":"Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances","volume":"1","author":"Guilmette","year":"2019","journal-title":"Adv Anat Pathol"},{"key":"R5-20260713","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/arpa.2019-0338-RA","article-title":"A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the new World Health Organization classification","volume":"11","author":"Fang","year":"2019","journal-title":"Arch Pathol Lab Med."},{"key":"R6-20260713","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization","volume":"4","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R7-20260713","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1245\/s10434-012-2285-7","article-title":"Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes","volume":"9","author":"Cheema","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R8-20260713","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis, and recent trend toward improved survival","volume":"10","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"R9-20260713","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"4","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"R10-20260713","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s11605-007-0263-3","article-title":"Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients","volume":"11","author":"Bilimoria","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"R11-20260713","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5946\/ce.2017.131","article-title":"Diagnosis of pancreatic neuroendocrine tumors","volume":"6","author":"Lee","year":"2017","journal-title":"Clin Endosc"},{"key":"R12-20260713","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s00261-018-1574-4","article-title":"Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance","volume":"11","author":"Lee","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"R13-20260713","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00261-015-0388-x","article-title":"Uncommon presentations of common pancreatic neoplasms: a pictorial essay","volume":"6","author":"D\u2019Onofrio","year":"2015","journal-title":"Abdom Imaging"},{"key":"R14-20260713","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.mric.2018.03.010","article-title":"MR imaging of pancreatic neuroendocrine tumors","volume":"26","author":"Lo","year":"2018","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"R15-20260713","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2214\/AJR.17.18417","article-title":"Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis","volume":"2","author":"Canellas","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"R16-20260713","doi-asserted-by":"crossref","first-page":"W472","DOI":"10.2214\/AJR.05.0809","article-title":"MRI of islet cell tumors of the pancreas","volume":"5","author":"Herwick","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"R17-20260713","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3748\/wjg.v26.i19.2305","article-title":"Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management","volume":"19","author":"Ma","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R18-20260713","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.1590\/0102-672020180001e1428","article-title":"Pancreatic neuroendocrine TUMORS: surgical resection","volume":"1","author":"Belotto","year":"2019","journal-title":"Arq Bras Cir Dig"},{"key":"R19-20260713","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14737140.2019.1703677","article-title":"Surgical management of pancreatic neuroendocrine tumors: an introduction","volume":"12","author":"Hain","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"R20-20260713","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/EUS-D-22-00028","article-title":"Small nonfunctional pancreatic neuroendocrine neoplasms: time for a step-up treatment approach?","volume":"1","author":"Rimba\u015f","year":"2023","journal-title":"Endosc Ultrasound"},{"key":"R21-20260713","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3348\/jkrs.1964.1.1.5","article-title":"What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on cancer staging system for pancreatic neuroendocrine neoplasms?","volume":"1","author":"Choe","year":"2019","journal-title":"Korean J Radiol"},{"key":"R22-20260713","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1148\/radiol.12112512","article-title":"Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management","volume":"1","author":"Sahani","year":"2013","journal-title":"Radiology"},{"key":"R23-20260713","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/cyt.12111","article-title":"Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index","volume":"6","author":"Weynand","year":"2014","journal-title":"Cytopathology"},{"key":"R24-20260713","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.dld.2017.10.007","article-title":"Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows","volume":"1","author":"Zilli","year":"2018","journal-title":"Dig Liver Dis"},{"key":"R25-20260713","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.gie.2005.10.034","article-title":"EUS-guided alcohol ablation of an insulinoma","volume":"7","author":"J\u00fcrgensen","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"R26-20260713","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/jcm14020495","article-title":"Endoscopic-ultrasound-guided radiofrequency ablation for pancreatic tumors","volume":"2","author":"Coluccio","year":"2025","journal-title":"J Clin Med"},{"key":"R27-20260713","first-page":"e1759","article-title":"Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature","volume":"12","author":"Imperatore","year":"2020","journal-title":"Endosc Int Open"},{"key":"R28-20260713","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/diagnostics13091561","article-title":"Approaching small neuroendocrine tumors with radiofrequency ablation","volume":"13","author":"Rossi","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R29-20260713","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ando.2019.04.001","article-title":"Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumor","volume":"3","author":"Barthet","year":"2019","journal-title":"Ann Endocrinol"},{"key":"R30-20260713","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.vgie.2020.01.004","article-title":"EUS-guided radiofrequency ablation of a pancreatic neuroendocrine tumor","volume":"5","author":"Dawod","year":"2020","journal-title":"VideoGIE"},{"key":"R31-20260713","first-page":"1099","article-title":"Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors","volume":"11","author":"Choi","year":"2018","journal-title":"Endoscopy"},{"key":"R32-20260713","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/MPA.0000000000000133","article-title":"Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety","volume":"43","author":"Rossi","year":"2014","journal-title":"Pancreas"},{"key":"R33-20260713","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/den.14681","article-title":"Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: systematic review and meta-analysis","volume":"4","author":"Khoury","year":"2024","journal-title":"Dig Endosc"},{"key":"R34-20260713","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/curroncol32020113","article-title":"Endoscopic ultrasound-guided locoregional treatments for pancreatic neuroendocrine neoplasms","volume":"2","author":"Masciangelo","year":"2025","journal-title":"Curr Oncol"},{"key":"R35-20260713","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiology.186.3.8381551","article-title":"Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression","volume":"3","author":"Semelka","year":"1993","journal-title":"Radiology"},{"key":"R36-20260713","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/radiology.214.2.r00fe32483","article-title":"Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity","volume":"2","author":"Thoeni","year":"2000","journal-title":"Radiology"},{"key":"R37-20260713","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1148\/rg.306105523","article-title":"Pancreatic endocrine tumors: radiologic-clinicopathologic correlation","volume":"6","author":"Lewis","year":"2010","journal-title":"Radiographics"},{"key":"R38-20260713","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euo.2023.04.007","article-title":"Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy","volume":"6","author":"Giganti","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"R39-20260713","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00261-018-1715-9","article-title":"Temporal changes in MRI appearance of the prostate after focal ablation","volume":"1","author":"H\u00f6tker","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"R40-20260713","first-page":"34","article-title":"Correlation between standardized uptake value of (68) Ga-DOTA-NOC positron emission tomography\/computed tomography and pathological classification of neuroendocrine tumors","volume":"1","author":"Kaewput","year":"2018","journal-title":"World J Nucl Med"},{"key":"R41-20260713","first-page":"426","article-title":"The value of (68) Ga-DOTATATE PET\/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature","volume":"5","author":"Mojtahedi","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R42-20260713","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2478\/raon-2023-0055","article-title":"Quantitative SSTR-PET\/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM","volume":"4","author":"Ingenerf","year":"2023","journal-title":"Radiol Oncol"},{"key":"R43-20260713","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","article-title":"68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors","volume":"9","author":"Haug","year":"2010","journal-title":"J Nucl Med"},{"key":"R44-20260713","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/jc.2019-00282","article-title":"Endoscopic ultrasound-guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors","volume":"7","author":"Oleinikov","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:00:45Z","timestamp":1783969245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001850","relation":{},"ISSN":["1532-3145"],"issn-type":[{"value":"1532-3145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"2025-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}